ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Recurrent Autoimmune Encephalitis in a Patient With Autoimmune Polyendocrine Syndrome Type 1.Case reports in critical care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionAutoimmune polyglandular syndromes (APS) encompass a broad spectrum of disorders. APS III is characterized by autoimmune thyroiditis (AT) plus any autoimmune disorder, excluding Addison's disease. METHODS AND
resultsThis study explores the link between GAD65 related-temporal lobe epilepsy (GAD-TLE) and APS III. We retrospectively analyzed 29 GAD-TLE patients. Eighteen patients (62%) experienced at least one autoimmune disease, and ten patients (56%) fulfilled diagnostic criteria for APS III. In addition to AT and GAD-TLE, five patients had type 1 diabetes mellitus, one patient had latent autoimmune diabetes in adulthood, one autoimmune alopecia, one pernicious anemia, one had celiac disease and one patient had autoimmune alopecia, vitiligo, autoimmune atrophic gastritis and psoriasis. Approximately 35 years after the onset of the first disease, the probability of having the second disorder is over 80%. In our cohort, GAD65 antibodies are more frequently linked to AT than to type 1 diabetes mellitus, despite their well-known association.
conclusionOur data suggests that GAD65-TLE may share a common pathophysiology and should be included among APS-III diagnostic criteria. These insights support the need for rigorous, multidisciplinary monitoring to prevent delays in diagnosis and treatment. This work enhances understanding of APS complexity and informs targeted management strategies for patients with overlapping endocrine and neurological autoimmune disorders.
Indexed as
Identifiers
40571861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.